BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

642 related articles for article (PubMed ID: 18035968)

  • 1. Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure.
    Hochhaus A
    Expert Opin Pharmacother; 2007 Dec; 8(18):3257-64. PubMed ID: 18035968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias.
    Jabbour E; Cortes J; Kantarjian H
    Expert Opin Investig Drugs; 2007 May; 16(5):679-87. PubMed ID: 17461740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isodicentric duplication of Philadelphia chromosome as a mechanism of resistance to dasatinib in a patient with chronic myeloid leukemia after resistance to imatinib.
    Loglisci G; Breccia M; Nanni M; Mancini M; De Cuia R; Cannella L; Salaroli A; Federico V; Serrao A; Loglisci MG; Santopietro M; Alimena G
    Leuk Lymphoma; 2011 Jul; 52(7):1372-5. PubMed ID: 21463110
    [No Abstract]   [Full Text] [Related]  

  • 4. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.
    Pavey T; Hoyle M; Ciani O; Crathorne L; Jones-Hughes T; Cooper C; Osipenko L; Venkatachalam M; Rudin C; Ukoumunne O; Garside R; Anderson R
    Health Technol Assess; 2012; 16(42):iii-iv, 1-277. PubMed ID: 23134589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.
    Wei G; Rafiyath S; Liu D
    J Hematol Oncol; 2010 Nov; 3():47. PubMed ID: 21108851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysis.
    Kobayashi Y; Sakamaki H; Fujisawa S; Ando K; Yamamoto K; Okada M; Ishizawa K; Nagai T; Miyawaki S; Motoji T; Usui N; Iida S; Taniwaki M; Uoshima N; Seriu T; Ohno R
    Int J Hematol; 2011 Jun; 93(6):745-749. PubMed ID: 21594763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
    Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
    N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dasatinib treatment for imatinib resistant or intolerant patients with chronic myeloid leukaemia.
    Li J; Xu G; Yu S; He L; Guo L
    J Int Med Res; 2011; 39(2):337-47. PubMed ID: 21672337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development.
    Breccia M; Alimena G
    Expert Opin Drug Saf; 2010 Sep; 9(5):713-21. PubMed ID: 20722490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
    Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
    Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dasatinib: is it all in the dose?
    Condorelli F; Genazzani AA
    BioDrugs; 2010 Jun; 24(3):157-63. PubMed ID: 20222756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
    Hochhaus A; Baccarani M; Deininger M; Apperley JF; Lipton JH; Goldberg SL; Corm S; Shah NP; Cervantes F; Silver RT; Niederwieser D; Stone RM; Dombret H; Larson RA; Roy L; Hughes T; Müller MC; Ezzeddine R; Countouriotis AM; Kantarjian HM
    Leukemia; 2008 Jun; 22(6):1200-6. PubMed ID: 18401416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.
    Guilhot F; Apperley J; Kim DW; Bullorsky EO; Baccarani M; Roboz GJ; Amadori S; de Souza CA; Lipton JH; Hochhaus A; Heim D; Larson RA; Branford S; Muller MC; Agarwal P; Gollerkeri A; Talpaz M
    Blood; 2007 May; 109(10):4143-50. PubMed ID: 17264298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacoeconomic benefits of dasatinib in the treatment of imatinib-resistant patients with chronic myelogenous leukemia.
    Taylor MJ; Scuffham PA
    Expert Rev Pharmacoecon Outcomes Res; 2009 Apr; 9(2):117-21. PubMed ID: 19402798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management.
    Jabbour E; Kantarjian H
    Am J Hematol; 2012 Nov; 87(11):1037-45. PubMed ID: 23090888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drugs offer new hope for patients with CML who are resistant to imatinib.
    Oestreicher P
    ONS Connect; 2007 Jul; 22(7):20-1. PubMed ID: 17694781
    [No Abstract]   [Full Text] [Related]  

  • 18. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.
    Redaelli S; Piazza R; Rostagno R; Magistroni V; Perini P; Marega M; Gambacorti-Passerini C; Boschelli F
    J Clin Oncol; 2009 Jan; 27(3):469-71. PubMed ID: 19075254
    [No Abstract]   [Full Text] [Related]  

  • 19. Therapy options in imatinib failures.
    Ramirez P; DiPersio JF
    Oncologist; 2008 Apr; 13(4):424-34. PubMed ID: 18448557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure.
    Quintas-Cardama A; Kantarjian H; Jones D; Nicaise C; O'Brien S; Giles F; Talpaz M; Cortes J
    Blood; 2007 Jan; 109(2):497-9. PubMed ID: 16990591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.